TransMedics price target lowered to $90 from $110 at Piper Sandler

Piper Sandler analyst Matt O’Brien lowered the firm’s price target on TransMedics (TMDX) to $90 from $110 and keeps an Overweight rating on the shares after attending the company’s inaugural analyst meeting. Management provided top-line guidance for 2025 and through 2028 that seems aggressive to Piper. The firm does believe they can generate strong revenue growth through the end of the decade and with significant earnings power late in the decade, that should prove attractive to investors.